Inari Medical PEERLESS Results Show Superiority Of FlowTriever Compared To Catheter-Directed Thrombolytics For Intermediate-Risk Pulmonary Embolism, Published In 'Circulation'; PEERLESS Met Its Primary Composite Endpoint
Inari Medical PEERLESS Results Show Superiority Of FlowTriever Compared To Catheter-Directed Thrombolytics For Intermediate-Risk Pulmonary Embolism, Published In 'Circulation'; PEERLESS Met Its Primary Composite Endpoint
Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed thrombolytics (CDT). The results were presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and Co-Global Principal Investigator (PI), during the Late-Breaking Clinical Trial Session at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. In recognition of the clinical relevance of the study, results were also simultaneously published in Circulation, the premier peer-reviewed journal of the American Heart Association (AHA).
Inari Medical, Inc.(纳斯达克:NARI)(“Inari”)是一家致力于治疗和改善患有静脉和其他疾病患者生活的医疗器械公司,今天宣布了前瞻性PEERLESS随机对照试验(RCT)的积极结果,比较了FlowTriever和导管直接溶栓(CDT)。这些结果由埃默里大学医学院医学教授、联合全球首席研究员(PI)之一Wissam Jaber博士在2024年转导介入心血管治疗(TCT)年度科学研讨会的最新临床试验分会上在华盛顿特区宣布。为了表彰该研究的临床重要性,结果同时发表在美国心脏协会(AHA)的权威同行评审期刊Circulation上。
PEERLESS met its primary composite endpoint (win ratio 5.01, p<0.001), driven by patients experiencing significantly fewer clinical deteriorations or therapy escalations, fewer ICU admissions, and shorter ICU lengths of stay with FlowTriever versus CDT. Patients also had faster recovery of clinical symptoms and hemodynamics, shorter hospital length of stay, and fewer 30-day readmissions.
PEERLESS实现了其主要的综合终点(胜率5.01,p